Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
A Comprehensive Approach to Selection of Adverse Drug Reactions for a Drug with Conditional Marketing Authorisation in the European Union.
Journal: Advances in therapy
Published: September 27, 2025
A Model for an Academia-Industry Collaboration for Pharmacovigilance and Pharmacoepidemiology.
Journal: Pharmaceutical medicine
Published: April 22, 2025
Safety Reporting for Auxiliary Medicinal Products in the Sibeprenlimab Phase-III Study According to the New European Union (536/2014) CT Regulation.
Journal: Current drug safety
Published: November 08, 2024
Five years of post-marketing liver safety data from the tolvaptan Risk Evaluation and Mitigation Strategy.
Journal: Clinical kidney journal
Published: June 26, 2024
Liver safety of tolvaptan in patients with autosomal dominant polycystic kidney disease: interim data from a post-authorization safety study.
Journal: Clinical kidney journal
Published: May 22, 2024
Enhancing the Efficiency of the Individual Case Safety Report (ICSR) Quality and Compliance through Automation.
Journal: Current drug safety
Published: February 14, 2023
Evaluating the impact of a Risk Evaluation and Mitigation Strategy with tolvaptan to monitor liver safety in patients with autosomal dominant polycystic kidney disease.
Journal: Clinical kidney journal
Published: January 12, 2022
Effect of Brexpiprazole on Prolactin and Sexual Functioning: An Analysis of Short- and Long-Term Study Data in Major Depressive Disorder.
Journal: Journal of clinical psychopharmacology
Published: November 02, 2020
Effect of Brexpiprazole on Prolactin: An Analysis of Short- and Long-Term Studies in Schizophrenia.
Journal: Journal of clinical psychopharmacology
Published: December 20, 2018
A Case of Concomitant Pseudocyesis and Couvade Syndrome Variant.
Journal: Psychopharmacology bulletin
Published: May 02, 2018
Showing 1-12 of 12
Last Updated: 09/26/2026